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Substituted. isocoumarins, their use in inhibiting serine 
proteases with trypsin-like, chymotrypsin-like and elas-
tase-like specificity and their roles as anticoagulant 
agents, and anti-inflammatory agents. 
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and warfarin acts as a vitamin K antagonist and inhibits 
the synthesis of coagulation factors. None of the antico-
agulant drugs, antithrombotic drugs, fibrinolytic agents 
and antiplatelet drugs are highly effective in all clinical 
ISOCOUMARINS WITH BASIC SUBSTITUENTS 
AS SERINE PROTEASES INHIBITORS, 
ANTICOAGULANTS AND 
ANTI-INFLAMMATORY AGENTS 
STATEMENT OF GOVERNMENT INTEREST 
5 situations and many induce side reactions (Von Kaulla 
in Burger's Medicinal Chemistry, Part II, Wolff ed, 
1979, pp 1081-1132, incorporated herein by reference). 
Coagulation disorders such as disseminated intravascu-This invention was made with government support 
under Contract No. HL 34035 awarded by the National 
Institutes of Health, National Heart, Lung and Blood 10 
Institute. The government has certain rights in the in-
vention. 
This application is a continuation-in-part of applica-
tion Ser. No. 043,647, filed on Apr. 28, 1987, now issued 
as U.S. Pat. No. 4,845,242 on July 4, 1989. 15 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
This invention relates to a novel class of heterocyclic 
compounds useful for selectively inhibiting trypsin-like 20 
enzymes, selectively inhibiting chymotrypsin-like en-
zymes, selectively inhibiting elastase or for generally 
inhibiting serine proteases of all classes. This invention 
also relates to a method of controlling blood coagula-
tion, tumor invasiveness and treating inflammation in 25 
patients using the novel compounds of the present in-
vention. We have found that substituted isocoumarins 
are potent inhibitors of blood coagulation enzymes, 
complement enzymes, tryptases, kallikreins, plasmin, 
chymases and elastase, therefore they are useful as anti- 30 
coagulants, anti-inflammatory and anti-tumor agents. 
2. Descriptiol). of the Related Art 
Serine proteases play critical roles in several physio-
logical processes such as digestion, blood coagulation, 
complement activation, fibrinolysis, and reproduction. 35 
Serine proteases are not only a physiological necessity, 
but also a potential hazard if they are not controlled. 
Blood coagulation serine proteases are responsible for 
vascular clotting, cerebral infarction, and comary in-
farction. Plasmin and plasminogen activator are in- 40 
volved in tumor invasiveness, tissue remodeling, and 
clot dissociation. Abnormal activation of complement 
enzymes may cause autoimmune hemolytic anemia, 
autoimmune thermocytopenia, leukopenia, glomerulo-
nephritis, systemic lupus erythematosus, serum sickness 45 
and periateritis nodosa. Uncontrolled proteolysis by 
elastases may cause pancreatitis, emphysema, rheuma-
toid arthritis, bronchial inflammation and adult respira-
tory distress syndrome. Accordingly, specific and selec-
tive inhibitors of these proteases should be potent anti· 50 
coagulants, anti-inflammatory agents and anti-tumor 
agents useful in the treatment of protease-related dis-
eases (Powers and Harper, in Proteinase Inhibitors, 
Barrett and Salvesen, eds., Elsevier, 1986, pp 55-152, 
incorporated herein by reference). In vitro proteolysis 55 
by trypsin, chymotrypsin or the elastase family is a 
serious problem in the production, purification, isola-
tion, transport or storage of peptides and proteins. 
Anticoagulants and antithrombotic drugs are used in 
a variety of thrombotic disorders. The 1986 Physician's 60 
Desk Reference list three anticoagulant drugs (heparin, 
protamine sulfate and warfarin), one antiplatelet drus 
(aspirin) and several thrombolytic agents. Heparin and 
warfarin are commonly used clinically for prevention 
and treatment of venous thrombosis and pulmonary 65 
embolism. Heparin inhibits the blood coagulation activ-
ity by accelerating the binding of natural plasma prote-
ase inhibitor antithrombin III with coagulation factors, 
lar coagulation, bleeding complications of medical and 
surgical procedures and bleeding complications of sys-
temic illness are still difficult to manage (Ingram, Bro-
zovic and Slater in Bleeding Disorders, Blackwell Sci-
entific Publications, 1982, pp 1-413). In the treatment of 
patients with coagulation problems, anticoagulant or 
antithrombotic agents of diverse mechanisms are ur-
gently sought in order to provide better medical care. 
Anti-inflammatory agents were used to treat elas-
tases-associated inflammation including rheumatoid 
arthritis and emphysema. Although the naturally occur-
ring protease inhibitor, al-protease inhibitor (al-Pl) 
has been used to treat patients with emphysema, this 
inhibitor is not widely used clinically due to the high 
dosage needed for the treatment and difficulty of pro-
ducing large qlllll!tities. Therefore small molecular 
weight elastase inhibitors are needed for therapy. 
SUMMARY OF THE INVENTION 
It is an object of this invention to find a novel group 
of specific inhibitors for trypsin, elastase, chymotrypsin 
and other serine proteases of similar substrate specificity 
and for serine proteases in general. Inhibitors are com-
pounds that reduce or eliminate the catalytic activity of 
the enzyme. Trypsin and trypsin-like enzymes normally 
cleave peptide bonds in proteins and peptides where the 
amino acid residue on the carbonyl side of the split bond 
(Pt residue) is Lys or Arg. Elastase and elastase-like 
enzymes, on the other hand, cleave peptide bonds 
where the Pt amino acid is Ala, Val, Ser, Leu and other 
similar amino acids. Chymotrypsin and chymotrypsin-
like enzymes hydrolyze peptide bonds where Pt amino 
acid is Trp, Tyr, Phe, Met, Leu or other amino acid 
residues which contain aromatic or large alkyl side 
chains. All of the above enzymes have extensive sec-
ondary specificity and recognize amino acid residues 
removed from the Pt residue. 
It is an object of this invention to discover new prote-
ase inhibitors, especially blood coagulation enzyme 
inhibitors, which can act as anticoagulants in vitro and 
in vivo. Such inhibitors could be used in prevention of 
thrombosis during periods of stasis and/or endothelial 
damage in the segments of vasculature. They could also 
be used in an adjunct to fibrinolytic therapy to prevent 
acute coronaries or peripheral arteries reclosure. The 
inhibitors of this invention would be useful as the sole 
method of maintaining anticoagulation in extracorpo-
real blood circuits such as the kidney hemodialysis, and 
heart lung bypass. Such inhibitors could also be used as 
alternate anticoagulants when conventional anticoagu-
lation with heparin or coumarin fail or is contraindi-
cated. The inhibitors of this invention wo_uld also be 
useful in the therapy for disseminated intravascular 
coagulation syndromes (DIC). They could also be used 
in prophylaxis against thrombosis in high risk situation 
involving myocardium (e.g. unstable angina). 
It is another object of this invention to discover new 
protease inhibitors, especially elastase inhibitors, com-
plement enzyme inhibitors, tryptase inhibitors, chymase 
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inhibitors and plasmin inhibitors. These inhibitors are 
useful for controlling tissue damage and various inflam-
matory conditions mediated by proteases particularly 
elastases. The inhibitors of this invention would be use- 5 ful for treating diseases relates to complement proteases 
or plasmin; such as autoimmune diseases and tumor 
invasiveness. The inhibitors of this invention would also 
be useful for controlling hormone processing by serine 
proteases and for treating diseases related to tryptases 10 
and chymases such as inflammation and skin blistering. 
It is a further object of this invention to find a novel 
group of specific inhibitors useful in vitro for inhibiting 
trypsin, elastase, chymotrypsin and other serine pro- 15 
teases of similar specificity and for inhibiting serine 
proteases in general. Such inhibitors could be used to 
identify new proteolytic enzymes encountered in re-
search. They could also be used in research and indus-
trially to prevent undesired proteolysis that occurs dur- 20 
ing the production, isolation, purification, transport and 
storage of valuable peptides and proteins. Such proteo-
lysis often destroys or alters the activity and/or func-
tion of the peptides and proteins. Uses would include 25 
the addition of the inhibitors to antibodies, enzymes, 
plasma proteins, tissue extracts or other proteins and 
peptides which are widely sold for use in clinical analy-
ses, biomedical research, and for many other reasons. 
For some uses a specific inhibitor would be desirable, 30 
while in other cases, an inhibitor with general specific-
ity would be preferred. 
0 
RYIY~ 
~z 
y 
(I) 
or a pharmaceutically acceptable salt thereof, wherein 
R is selected from the group consisting of -N-
H-C( NH)NH2, -C( NH)NH2, amino-C1-6 alkyl, 
and C1-6 alkyl with an isotheiureido group of the for-
mula -S-C( NH)NH2 attached to the alkyl group, 
Z is selected from the group consisting ofH, halogen, 
C1-6 alkyl, C1-6 alkyl with a phenyl group attached to 
the alkyl group, C1-6 fluorinated alkyl, C1-6 alkyl with a 
hydroxyl group attached to the alkyl group, C1-6 alkyl 
with a C1-6 alkoxy attached to the alkyl group, C1-6 
alkoxy, C1-6 fluorinated alkoxy, C1-6 alkoxy with a 
phenyl group attached to the alkoxy group, benzyloxy 
group wherein the phenyl group is unsubstituted or 
substituted by one or two substituents selected from 
halogen, trifluoromethyl, N02, cyano, methyl, me-
thoxy, acetyl, carboxyl, OH, and amino, and 
Y is selected from the group consisting of H, halogen, 
trifluoromethyl, methyl, OH, and methoxy. 
Alternately the novel isocoumarin and related heter-
ocyclic compounds are represented by structure (I) 
where, 
Z is selected from the group consisting of C 1-6 alkoxy 
with an amino group attached to the alkoxy group, C1-6 
alkoxy with an isothiureido group attached to the alk-
oxy group, C1-6 alkoxy with a guanidino group attached DETAILED DESCRIPTION OF THE 
INVENTION 35 to the alkoxy group, C1-6 alkoxy with an amidino group 
attached to the alkoxy group, C1-6 alkyl with an amino 
group attached to the alkyl group, C1-6 alkyl with an 
isothiureido group attached to the alkyl group, C1-6 
Substituted isocoumarins have been found to be ex-
cellent inhibitors of several serine proteases including 
bovine thrombin, bovine factor Xa, human factor Xa, 
human factor Xia, human factor Xlla, human factor 40 
Vila, human plasma kallikrein, porcine pancreatic kalli-
krein, brovine trypsin, human plasma plasmin, human 
tissue plasminogen activator, sheep lung lymph tryp-
tase, human lung tryptase, rat skin tryptase, human 45 
complement proteins Ctr, Cls, D, B, C2, human leuko-
cyte elastase, porcine pancreatic elastase, bovine chy-
motrypsin and human leukocyte cathepsin G, rat mast 
cell protease II, human skin chymase, human lung chy-
mase, mouse cytotoxic T lymphocyte granzyme A, 50 
human cytotoxic T lymphocyte granzyme A and 
human Q31 cytotoxic T lymphocyte tryptase. These 
compounds inhibit the serine proteases by reaction with 
the active site serine to form an acyl enzyme, which in 55 
some cases may further react with another active site 
nucleophile to form an additional covalent bond. These 
structures may be used in vivo to treat diseases resulting 
from abnormal complement activation or uncontrolled 
blood coagulation or diseases caused by untrolled pro- 60 
teolysis by elastase, chymotrypsin, trypsin and related 
serine proteases. These inhibitors may be used in vitro 
to prevent proteolysis which occurs in the process of 
production, isolation, purification, storage or transport 65 
of peptides and proteins. The novel substituted 
isocoumarin and related heterocycic compounds have 
the following structural formula: 
alkyl with a guanidino group attached to the alkyl 
group, C1-6 alkyl with an amidino group attached to the 
alkyl group, 
R is selected from the group consisting of H, OH, 
NH2, N02, halogen, C1-6 alkoxy, C1-6 fluorinated alk-
oxy, C1-6 alkyl, amino-C1-6 alkyl, M-AA-NH-, 
M-AA-0-, 
wherein AA represents alanine, valine, leucine, iso-
leucine, proline, methionine, phenylalanine, tryptophan, 
glycine, serine, theonine, cysteine, tyrosine, asparagine, 
glutamine, aspartic acid, glutamic acid, lysine, arginine, 
histidine, beta-alanine, norleucine, norvaline, alpha-
aminobutyric and epsilon-aminocaproic acid, citrulline, 
hydroxyproline, ornithine and sarcosine, 
wherein M represents H, lower alkanoyl having 1 to 
6 carbons, carboxyalkanoyl, hydroxyalkanoyl, amino-
alkanoyl, benzene sulfonyl, tosyl, benzoyl, and lower 
alkyl sulfonyl having 1 to 6 carbons, and 
Y is selected from the group consisting of H, halogen, 
trifluoromethyl, methyl, OH and methoxy. 
Alternately the novel isocoumarin and related heter-
ocyclic compounds are represented by structure (I) 
wherein, 
R is selected from the ·group consisting of -N-
H-C( NH)NH2, -( NH)NH2, amino-C1-6 alkyl, 
isothiureido-C1-6 alkyl, 
Z is selected from the group consisting of C 1-6 alkoxy 
with an amino group attached to the alkoxy group, C1-6 
alkoxy with an isothiureido group attached to the alk-
oxy group, C 1-6 alkoxy with a guanidino group attached 
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to the alkoxy group, Ct-6 alkoxy with an amidino group tive inhibition of the proteolytic function of sheep lung 
attached to the alkoxy group, Ct-6 alkyl with an amino lymph tryptase and human lung tryptase. Sheep lung 
group attached to the alkyl group, Ct-6 alkyl with an lymph tryptase is utilized as a marker of lung capillary 
isothiureido group attached to the alkyl group, Ct-6 injury, and this is shown in the articles by Lesser et al., 
alkyl with a guanidino group attached to the alkyl S Am. Rev. Respir. Dis. 135, pp 643-650 (1987) and by 
group, Ct-6 alkyl with an amidino group attached to the Orlowski et al., Arch. Biochem. Biophys. 269, pp 
alkyl group, and 125-136 (1989), which are incorporated herein by refer-
y is selected from the group consisting ofH, halogen, ence. Compounds of Formula (I) have anti-inflamma-
trifluoromethyl, methyl, OH and methoxy. tory activity and are effective in the prevention and 
Other substituted isocoumarins have been prepared 10 inhibition of edema and granuloma tissue formation as 
earlier for other purposes (illustrative examples: Davies shown in Table IV by the effective inhibition of the 
and Poole, J. Chem. Soc., pp 1616-1629 (1928); Milev- proteolytic function of human leukocyte elastase. Com-
skaya, Belinksaya, and Yagupol'skii, Zhur. Org. Khim. pounds of Formula (I) are effective in treating a variety 
9, pp 2145-2149 (1973); Tirodkar and Usgaonkar, Ind. J. of blistering diseases as shown in Table III and Table V 
Chem. 7, pp 1114-1116 (1969); Choksey and Usgaonkar, IS by the effective inhibition of proteolytic function of rat 
Ind. J. Chem. 14B, pp 596-598 (1976), the preceding skin tryptase and human skin chymase. It has been 
articles are incorporated herein by reference). found that compounds of Formula (I) have anti-tumor 
A number of other substituted isocoumarins have activity as shown in Table VI by the effective inhibition 
been prepared recently for inhibition of serine proteases of the proteolytic function of human plasma plasmin 
(Harper, Hemmi, and Powers, J. Am. Chem. Soc. 105, 20 and human tissue plasminogen activator. 
pp 6518-6520 (1983); Harper, Hemmi, and Powers, Inactivation rates of serine proteases by substituted 
Biochemistry 24, pp 1831-1841 (1985); Harper and isocoumarins were measured by the incubation method. 
Powers, J. Am. Chem. Soc. 106, pp 7618-7619 (1984); An aliquot of inhibitor (25 or 50 µl) in Me2SO was 
Harper and Powers, Biochemistry 24, 7200-7213 added to a buffered enzyme solution (0.01-2.3 µ.M) to 
(1983); Kam, Fujikawa and Powers, Biochemistry 27, 25 initiate the inactivation. Aliquots (50 µ.l) were with-
pp 2547-2557 (1988); Powers, Kam, Narasimhan, Olek- drawn at various intervals and the residual enzymatic 
syszyn, Hernandez and Ueda, J. Cell Biochem. 39, pp activity was measured. Me2SO concentration in the 
33-46 (1989), the preceding articles are incorporated reaction mixture was 8-12% (v/v). 0.1 Hepes, O.OlM 
herein by reference; and Powers and Harper, U.S. Pat. CaCh, pH 7.5 buffer was utilized for trypsin and coagu-
No. 4,596,822, which is also incorporated by reference). 30 lation enzymes. O.lM Hepes, 0.5M NaCl, pH 7.5 was 
The following compounds are representative of the utilized for other serine proteases. The inhibitor con-
invention: centrations are shown in the Tables I, II, III, IV, V, VI, 
3-(3-aminopropoxy)isocoumarin and VII. Peptide thioesters or peptide nitroanilides with 
3-(3-aminopropoxy)-4-chloroisocoumarin appropriate sequence were used as substrates for vari-
3-(2-isothiureidoethoxy)-4-chloroisocoumarin 35 ous serine proteases. All peptide thioester hydrolysis 
3-(3-isothiureidopropoxy)-4-chloroisocoumarin rates were measured with assay mixtures containing 
7-amino-3-(2-isothiureidoethoxy)-4-chloroisocoumarin 4,4'-dithiodipyridine (E324= 19800M- lcm-1; Grasetti 
7-amino-3-(3-isothiureidopropoxy)-4-chloroisocouma- & Murray, Arch. Biochem. Biophys. 119, pp 41-49 
rin (1967)). Peptide 4-nitroanilide hydrolysis was measured 
7-guanidino-3-methoxyisocoumarin 40 at 410 nm (E410=8800M-lcm-l; Erlanger et al., Arch. 
7-guanidino-3-methoxy-4-chloroisocoumarin Biochem. Biophys. 95, pp 281-278 (1961)). First order 
7-guanidino-3-ethoxyisocoumarin inactivation rate constant <kohs) were obtained from 
7-guanidino-3-ethoxy-4-chloroisocoumarin plots ofln vr/v0 vs time, and the correlation coefficients 
7-guanidino-3-(2-phenylethoxy)isocoumarin were greater than 0.98. 
7-guanidino-3-(2-phenylethoxy)-4-chloroisocoumarin 45 Table I shows the inactivation rate constants for sev-
7-(alanylamino)-3-methoxy-4-chloroisocoumarin eral trypsin-like serine proteases inhibited by substituted 
7-(glycylamino)-3-methoxy-4-chloroisocoumarin isocoumarins. When the isocoumarin structure contains 
It has been found that compounds of Formula (I) basic functional groups such as guanidino as R, or 
have anticoagulant activity as shown in Table I by ef- amino-alkoxy, isothiureidoalkoxy as Z, and Cl as Y, the 
fective inhibition of the proteolytic function of blood SO compound is generally a good inhibitor for trypsin and 
coagulation enzymes in Hepes buffer. Compounds of blood coagulation enzymes and tryptases. The inactiva-
Formula (I) also have anticoagulent effect in vitro as tion of the enzyme is time dependent, and the kobsl[I] 
shown in Table IX by prolongation of the prothrombin values are second order rate constants. In most cases, 
time (P'I) and activated partial thromboplastin time inactivation of the enzyme occurs at the inhibitor con-
(APTT) in human and rabbit plasma. It has also been 55 centration of 5-400 times the enzyme concentration and 
found that compounds of Formula (I) have anticoagu- the first order rate constant kobs is obtained. However, 
lant effect in vivo as shown in Table X and Table XI by in some cases, the inactivation was too fast to be mea-
prolongation the APTT with continuous infusion of sured under first order rate condition ([I]> [E]), the 
7-amino-3-(3-isothiureidopropoxy)-4-chloroisocouma- inactivation rate was measured either in the presence of 
rin into rabbits. 60 substrate using the progress curve method as described 
It has been found that compounds of Formula (I) are by Tian. and Tsou, Biochemistry 21, pp 1028-1032 
effective in the treatment of organ rejection and autoim- (1982) or using the same concentration of enzyme and 
mune diseases as shown in Table II by the effective inhibitor. 7-guanidino-4-chloro-3-alkoxyisocoumarins 
inhibition of the proteolytic function of complement are essentially stoichiometric inactivators of trypsin, 
proteins. Compounds of Formula (I) are effective in the 6S thrombin and kallikrein. The inactivation rate of the 
detection, prevention and inhibition of adult and infan- enzyme depends on the substituents R, Z and Y. The 
tile respiratory distress syndrome (a consequence of structures with R groups of guanidino, and Y groups of 
acute lung injuries) as shown in Table III by the effec- Cl are the best inhibitors for trypsin and all the coagula-
7 
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tion enzymes tested. The isocoumarins with Y groups of propoxy)-4-chloroisocoumarin show more effect on 
Cl and Z groups ofisothiureidoalkoxy are potent inhibi- APTT than PT. With normal citrated human plasma, 
tors toward trypsin-like enzymes. 7-guanidino-3-ethoxy-4-chloroisocoumarin prolong PT 
Table II shows the inactivation ofcomplement prote- 1.8 fold and prolong APTT more than 4.5 fold at 21 
ins D, B, C2, cir, Cls, and their .active fragments C2a, 5 µ.M, and 7-amino-3-(3-isothiureidopropoxy)-4-
Bb by substituted isocoumarins. The isocoumarin with chloroisocoumarin prolong APTT more than 4.5 fold 
R groups of amino or hydrogen, Z groups of isothi- and increase PT 1.5 fold at 29 µ.M. Both compounds 
ureidopropoxy, and Y groups of chloro inhibit Clf and have smaller effect in rabbit plasma. 
Cls quite potently. 7-Guanidino-3-alkoxy-4- Table X shows the dose-response data of 7-amino-3-
chloroisocoumarin inhibit cir, Cls, Band Bb moder- 10 (3-isothiureidopropoxy)-4-chloroisocoumarin on 
ately. Although 3-isothiureidoalkoxy-4- APTT when this compound was administered into rab-
chloroisocoumarins inhibit protein B and C2 poorly, bits with continuous infusion. 7-Amino-3-(3-isothi-
while other serine protease inhibitors such as 4-amidino- ureidopropoxy)-4-chloroisocoumarin prolonged the 
phenylmethane sulfonyl fluoride (APMSF) and 3,4- APTT two fold over control values at lowest dose of 
dichloroisocoumarin do not show any inhibition toward 15 0.4 mg/ml, whereas at the highest dose of 1.2 mg/ml the 
these two enzymes. Table III shows the inactivation of APTT is prolonged 3 to 4 times control. Table XI 
sheep lung lymph tryptase, human lung tryptase and rat shows the APTT and activated clotting time (ACT) of 
skin tryptase by substituted isocoumarins. The structure 7-amino-3-(3-isothiureidopropoxy)-4-chloroisocouma-
with R group of guanidino, Z group of alkoxy, and Y rin with a continuous infusion of 0.8 mg/ml to rabbits 
group of chloro are good inhibitors for sheep lung 20 for 17 min. At 16 min during the infusion, this com-
lymph tryptase. The isocoumarins with R groups of pound prolongs APTT 2.3 fold and prolongs ACT 1.4 
guanidino or amino, Z groups of alkoxy or isothiureido- fold. 
propoxy, and Y groups of chloro are potent inhibitors Anticoagulants can prolong the clotting time of 
for human lung tryptase and rat skin tryptase. Table IV human plasma and play important roles in the treatment 
shows the inactivation rate eonstants for porcine pan- 25 of blood coagulation related diseases such as vascular 
creatic elastase (PPE), human leukocyte elastase clotting, cerebral infarction and comary infarction 
(HLE), chymotrypsin and cathepsin G inhibited by (Williams et al., Hemotalogy, 3rd ed. McGraw Hill, 
substituted isocoumarins. Although the inactivation by 1983 and Ingram et al., Bleeding Disorders, 2nd ed. 
the inhibitors was less efficient toward these four en- Blackwell Scientific Publications, 1985. These two 
zymes than trypsin-like enzymes, the isocoumarin with 30 books are incorporated herein by reference). The pres-
R group of guanidino, Y group of Cl, and Z-group of cence of certain inhibitors of this invention in the 
ethoxy is a good inhibitor for PPE, HLE and cathepsin human and rabbit plasma prolong the prothrombin time 
G. The structure with Z-group of 2-phenylethoxy is and activated partial thromboplastin time quite effec-
best at inhibiting chymotrypsin. tively, therefore these compounds act as anticoagulants 
Table V shows the inactivation of rat mast cell prote- 35 in vitro. One of these isocoumarins, 7-amino-3-(3-isothi-
ase II, human skin chymase and human lung chymase ureidopropoxy)-4-chloroisocoumarin also showed pro-
by substituted isocoumains. The structure with R group longation on APTT when it was administered into rab-
of guanidino, Z group of alkoxy, and Y group of chloro bits with continuous infusion. Thus these inhibitors 
werre potent inhibitors for rat mast cell protease II and would act as anticoagulants in vivo. Currently, there 
were moderate inhibitors for human skin chymase and 40 are a few anticoagulant and antithrombotic drugs in use 
human lung chymase. Table VI shows the inactivation clinically, and the inhibitors described in this invention 
rate constants for human plasmin and human tissue can be used as anticoagulants or antithrombotics in the 
plasminogen activator by substituted isocoumarins. The treatment of mammals (including man). 
structure with R groups of amino, hydrogen or It is known that in vitro activity of elastase inhibitors 
guanidino, Z groups of isothiureidoalkoxy or alkoxy, 45 correlates with in vivo activity in animal models of 
and Y groups of chloro inhibited both enzymes po- emphysema and inflammation (Ottemess et al., editor, 
tently. Table VII shows the inactivation of mouse gran- Advances in Inflammation Research, Vol. 11, Raven 
zyme A, human granzyme A and human Q31 tryptase Press 1986, and this article is incorporated herein by 
by substituted isocoumarins. The isocoumarins with R reference). Thus the novel inhibitors described here 
groups of hydrogen, amino or guanidino, Z groups of SO should be useful for the treatment of emphysema and 
isothiureidoalkoxy or alkoxy, and Y groups of chloro inflammation. Elastase inhibitors have been used orally, 
were potent inhibitors for all three tryptases. by injection or by instillation in the lungs in animal 
The spontaneous hydrolysis rates of these substituted studies (Powers, Am. Rev. Respir. Dis., 127, s54-s58 
isocoumarins in Hepes buffer, human and rabbit plasma (1983); Powers and Bengali, Am. Rev. Respir. Dis. 134, 
have been measured and summarized in Table VIII. 55 pp 1097-1100 (1986) and these two articles are incorpo-
The isocoumarins with hydrogen at position 4 are 3-6 rated herein by reference). The inhibitors described 
times more stable than the compounds with Cl at the above can be used by any of these routes. 
same position. 7-Amino-4-chloro-3-(3-isothiureido- For treatment of blood coagulation-related diseases, 
propoxy)isocoumarin is fairly stable in both human and tumor invasiveness or inflammation, the compounds of 
rabbit plasma. 7-Guanidino-4-chloro-3-alkox- 60 Formula (I) or pharmaceutically acceptable salts may 
yisocoumarins are hyprolyzed in human and rabl?it be administered orally, topically or parenterally. The 
plasma with half-lives of 5-8 min. term parenteral as used includes subcutaneous injection, 
Table IX shows the anticoagulant effect of substi- intravenous, intramuscular, intrastemal injection or 
tuted isocoumarins in human and rabbit plasma. The infusion techniques. The dosage depends primarily on 
prothrombin time (PT) and activated partial thrombo- 65 the specific formulation and on the object of the therapy 
plastin time (APTT) were measured in the presence of or prophylaxis. The amount of the individual doses as 
various inhibitors. 7-Guanidino-3-ethoxy-4- well as the administration is best determined by individ-
chloroisocoumarin and 7-amino-3-(3-isothiureido- ually assessing the particular case. 
9 
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The pharmaceutical compositions containing the ac-
tive ingredient may be in a form suitable for oral use, for 
example as tablets, troches, lozenges, aqueous or oily 
suspensions, dispersible powders or grannules, emul-
sions, hard or soft capsules or syrups or elixirs. Dosage s 
levels of the order to 0.2 mg to 140 mg per kilogram of 
body weight per day are useful in the treatment of 
above-indicated conditions (10 mg to 7 gms per patient 
per day). The amount of active ingredient that may be 
combined with carrier materials to produce a single 10 
dosage form will vary depending upon the host treated 
and the particular mode of administration. 
For injection, the therapeutic amount of the com-
pounds of Formula (I) or their pharmaceutically accept-
able salts will normally be in the dosage range from 0.2 lS 
to 140 mg/kg of body weight. Administration is made 
by intravenous, intramuscular or subscutaneous injec-
tion. Accordingly, pharmaceutical compositions for 
parenteral administration will contain in a single dosage 
form about 10 mg to 7 gms of compounds of Formula 20 
(I) per dose. In addition to the active ingredient, these 
pharmaceutical compositions will usually contain a 
buffer, e.g. a phosphate buffer which keeps the pH in 
the range from 3.5 to 7 and also sodium chloride, manni-
tol or sorbitol for adjusting the isotonic pressure. 2S 
A composition for topical application can be formu-
lated as an aqueous solution, lotion, jelly or an oily 
solution or suspention. A composition in the form of an 
aqueous solution is obtained by dissolving the com-
pounds of Formula (I) or their pharmaceutically accept- 30 
able salts in aqueous buffer solution of pH 4 to 6.5 and 
if desired, adding a polymeric binder. An oily formula-
tion for topical application is obtained by suspending 
the compounds of Formula (I) or their pharmaceuti-
cally acceptable salts in an oil, optionally with the addi- 35 
tion of a swelling agent such as aluminium stearate 
and/ or a surfactant. 
In addition to the compounds of Formula (I) or their 
pharmaceutically acceptable salts which are intended 
for medicinal use on the human or animal body, the 40 
present invention also relates to the compounds of For-
mula (I) or their pharmaceutically acceptable salts for 
the medicinal use outside the living body of humans or 
animals. Such compounds are used as anticoagulants for 
blood which is subjected to extracorporeal circulation 4S 
or treatment such as kidney hemodialysis, heat lung 
bypass, or ultraftltration. Such preparation are similar in 
composition and are similar to the above described 
injection preparations. However, the amount of active 
ingredient is conveniently based on the volume of the SO 
blood to be treated. In such treatment, the compound of 
Formula (I) or their pharmaceutically acceptable salts 
must be eilminated from the blood rapidly even in large 
concentration so that there is no danger of overdosage. 
Depending on the specific purpose, the suitable dose is SS 
from 2 mg to 1.4 gms of the active ingredient per liter of 
blood. 
To use the above inhibitors in vitro, they are dis-
solved in an organic solvent such as dimethylsulfoxide 
or ethanol, and are added to an aqueous solution con- 60 
taining serine proteases. The final concentration of the 
organic solvent should be less than 25%. The inhibitors 
may also be added as solids or in suspension. The serine 
protease inhibitors of this invention would be useful in a 
variety of experimental procedures where proteolysis is 65 
a significant problem. Inclusion of these inhibitors in a 
radioimmunoassay experiments would result in higher 
sensitivity. The use of these inhibitors in plasma frac-
tionation procedures would result in higher yields of 
valuable plasma proteins and would make purification 
of the proteins easier. The inhibitors disclosed here 
could be used in cloning experiments utilizing bacterial 
cultures, yeast and purified cloned product in higher 
yield. 
The following examples are given to illustrate the 
invention and are not intended to limit it in any manner. 
EXAMPLE 1 
Preparation of 
3-(2-Isothiureidoethoxy )-4-Chloroisocoumarin 
2-Bromoethyl 2-carboxyphenylacetate was prepared 
from heating 10 g ofhomophthalic acid (56 mmole) and 
21 g of2-bromoethanol (167 mmole) in 175 ml of ben-
zene with a few drops of cone. sulfuric acid at 90° -110° 
C. for two hours, yield 64%. TLC shows that it is a pure 
compound. The cyclization of 2-bromoethyl 2-carbox-
yphenylacetate with PCls was performed by a previous 
method with modification (Tirodkar, and Usgaonkar, 
Indian. J. Chem. 7, pp 114-1116 (1969)). 1.15 g of 2-
bromoethyl 2-carboxyphenylacetate was heated with 
2.1 g of PCls in 90 ml of benzene at 70° C. for 2 hrs. The 
benzene was removed and the residue triturated with 
petroleum ether. The crude product was purified by 
silica gel column chromatography with methylene 
chloride as an eluent to give 560 mg of 3-(bromoethyl)-
4-chloroisocoumarin (yield, 46% ). IR and NMR spectra 
show it was the desired product. 100 mg of 3-bromoeth-
yl-4-chloroisocoumarin (0.3 mmole) was heated with 60 
mg ofthiourea (0.8 mmole) in S ml ofTHF at 70° C. for 
2 days to give a yellow solid, SO mg (yield, 40%), m.p. 
167°-169° C. (dee); one spot on TLC, RF=0.7 (Buta-
nol:acetic acid:water=6:1:5); NMR spectrum (d6-
DMSO), 89.1 (2b, 4H), 7.5-8.l (m, 4H), 4.6 (t, 2H), 3.6 
(t, 2H); mass spectrum (FAB+), m/e=299 (M+-Br). 
Anal. Cale. for C12H12N203Br1Cl1S2: C, 37.96; H, 3.19; 
N, 7.38. Found: C, 37.81; H, 3.28; N, 7.71. 
EXAMPLE2 
Preparation of 7-Guanidino-3-Methoxyisocoumarin 
Methyl 2-carboxy-4-nitrophenyl acetate was pre-
pared from 2-carboxy-4-mtrophenylacetate and metha-
nol by the procedure described above. Hydrogenation 
of this nitro compound gives methyl 4-amino-2-car-
boxy-phenylacetate (yield 90%). The guanidination of 
the amino compound with 3,5-dimethylpyrazole-1-car-
boxamidine nitrate (ADMP) was preformed by a stan-
dard method described previously (Tsunematsu & 
Makismi, J. Biochem. 88, pp 1773-1783, (1980)). 2.2 g of 
amino compound (10 mmole), 1.9 g oftriethylamine (19 
mmole) and 3.0 g of ADMP (15 mmole) was heated in 
20 ml ofTHF and refluxed for 18 hrs. The white precip-
itate was filtered and washed with cold methanol to 
give 1.5 g of methyl 2-carboxy-4-guanidinophenylace-
tate, (yield 46%). One spot on TLC, Rf=0.6 (Butanol:a-
cetic acid:pyridine:water=4:1:1:2), it shows an orange 
color when sprayed with Sakaguchi reagent. NMR 
spectrum (CF3COOH), 88.4, 7.7 (b, 4H), 6.6 (b, 4H) 4.4 
(s, 2H), 4.1 (s, 3H). Anal. Cale. for C11H13N3Q4.lH20: 
C, 50.77; H, 5.42; N, 16.15. Found: C, 51.03; H, 5.38; N, 
16.19. 0.9 g of methyl 2-carboxy-4-guanidinophenylace-
tate (3 mmole) was heated with 1.S g of PCls (7.2 
mmole) at 70°-80° C. for 2 hrs, white solid precipitated 
out during the heating. The solid was filtered off and 
purified by silica gel column chromatography with 
methylene chloride and methanol (5:1) as an eluent to 
4,954,519 
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give 0.5 g of 7-guanidino-3-methoxyisocoumarin (yield 
59%). One spot on TLC, Rf=0.7 (Butanol:acetic acid:-
pyridine:water=4:1:1:2); m.p. 185°-186° C. (dee);, 
NMR spectrum (d6·DMOS): 87.9, 7.6 (b, 3H), 7.7 (b, 
4H), 6.1 (s, lH), 3.9 (s, 3H); mass spectrum (FAB+), 5 
m/e=234 (M+-Cl). Anal. Cale. for C11H12N303Clt.l 
H10: C, 47.40; H, 4.67; N, 15.08; Cl, 12.75. Found: C, 
47.42; H, 4.74; N, 15.05; Cl, 12.68. 
gel column chromatography (methylene chloride:me-
thanol= 5: l) and crystallized from MeOH-ether to give 
0.009 g of 3-(3-aminopropoxy)-4-chloro-isocoumarin 
hydrochloride (yield, 60%). The NMR spectrum of this 
compound is similar to 3-(3-aminopropoxy)isocoumarin 
without the peak at 86.2 ppm; m.p. 160°-163° C.; mass 
spectrum, m/e=254 (M+-CI). Anal. Cale. for 
C12H13N103Ch.lH20: C, 48.88; H, 4.61; N, 4.75; Cl, EXAMPLE3 
Preparation of 
7-Guanidino-3-Methoxy-4-Chloroisocoumarin 
10 24.06. Found: C, 48.85; H, 4.54; N, 4.74; Cl, 24.02. 
0.27 g of 7-guanidino-3-methoxyisocoumarin (1 
mmole) was chlorinated with 0.15 g ofN-chlorosuccini-
mide (1.1 mmole) in S ml DMF at r.t. overnight. The 15 
reaction mixture was evaporated to dryness, and puri-
fied by silica gel column chromatography which is 
eluted with methylene chloride and methanol (5:1) to 
give 0.1 g of 7-guanidino-3-methoxy-4-chloroisocouma-
rin (yield 34%). One spot on TLC, Rf=0.75 (Butanol:a- 20 
cetic acid:pyridine:water=4:1:1:2); NMR spectrum is 
similar to 7-guanidino-3-methoxyisocoumarin except no 
peak at 6.1 ppm; mass spectrum (FAB+), m/e=268 
(M+-CI). Anal. Cale. for C11H11N303Ch.lH20: C, 
42.17; H, 3.83; N, 13.41; Cl, 22.68. Found: C, 42.65; H, 25 
3.72; N, 13,28; Cl, 22.32. 
EXAMPLE4 
EXAMPLE6 
Preparation of 
7-Amino-4-Chloro-3-(3-Isothiureidopropox-
y)isocoumarin 
This compound was synthesized by the same proce-
dure as 3-(3-isothiureidopropoxy )-4-chloroisocoumarin. 
3-Bromopropyl 2-carboxy-4-nitrophenylacetate was 
prepared from 2-carboxy-4-nitrophenylacetate and 3-
bromopropanol, yield 60%. Cyclization of the monoes-
ter with PCls gives 3-bromopropoxy-4-chloro-7-
nitroisocoumarin (yield, 60%). Hydrogenation of the 
nitro compound (0.36 g) in methanol gives 0.12 g of 
7-amino-3-bromopropoxy-4-chloroisocoumarin, which 
is purified by silica gel column chromatography with 
methylene chloride as an eluent (yield, 36% ). This 
Preparation of 3-(3-Aminopropoxy)isocoumarin 
Hydrochloride 30 aminoisocoumarin reacts with thiourea in THF to give the final product, which can be crystallized from 
MeOH-ether (yield, 40%), mp 160°-162° C. (dee); one 
spot on TLC, Rf=0.6 (Butanol:acetic acid:pyridine 
Homophthalic acid (18 g, 0.1 mole) and 3-(benzylox-
ycarbonylamino)-1-propanol (41 g, 0.2 mole) were 
heated in 150 ml of benzene at 120°-130° C. for 2 hrs in 
the presence of a few drops of cone. H1S04. Benzene 35 
was evaporated, and 200 ml of ethylacetate was added. 
The organic solution was washed with 4% NaHC03 
twice (150 mlX2). The aqueous layer which contained 
the monoester salt was acidified with 5N HCl and ex-
tracted with ethylacetate. 33 g of 3-(benzyloxycar- 40 bonylamino )propyl 2-carboxyphenylacetate (yield, 
89%) was obtained after the solvent was evaporated. 
Hydrogenation of this monoester (1.86 g, 5 mmole) was 
performed in methanol containing 0.3 ml of acetic acid 
and 10% palladium on carbon to give 1 g of 3-amino- 45 propyl 2-carboxphenylacetate.HAc (yield, 67%). This 
compound was identified by its NMR spectrum and 
TLC (Butanol:acetic acid:pyridine:water=4:1:1:2). 1 g 
of 3-aminopropyl 2-carboxyphenylacetate.HAc (3 
mmole) was heated with 1.6 g of PCls (7.5 mmole) in 50 50 
ml of anhydrous THF at 70° -so· C. for 2 hrs, a white 
precipitate formed. This white solid was purified by 
column chromatography (methylene chloride:me-
thanol = 5: l) and crystallized from MeOH-ether to give 
0.2 g of 3-(3-aminopropoxy)isocoumarin.HCI (yield, 55 26%), m.p. 173°-174° C.; mass spectrum, m/e=220 
(M+-CI). Anal. Cale. for C12H1~103ClJ: C, 56.37; H, 
5.52; N, 5.48; Cl, 13.87. Found: C, 56.15; H, 5.49; N, 
5.44; Cl 13.95. 
water=4:1:1:2); mass spectrum (FAB+), m/e=328 
(M+-Br). Anal. Cale. for C13H15N303Cl1BriS1: C, 
38.20; H, 3.70; N, 10.28; Cl, 8.67. Found: C, 38.15; H, 
3.73; N, 10.25; Cl, 8.63. 
EXAMPLE7 
Preparation of 
7-(Alanylamino )-3-Methoxy-4-Chloroisocoumarin 
Hydrochloride 
7-(N-a-Boc-alanylamino )-3-methoxy-4-
chloroisocoumarin was synthesized by reaction of Boc-
Ala (1 g, 5.5 mmole) with 1,3-dicyclohexylcarbodiimide 
(0.57 g, 2.8 mmole) at o• C. in THF for a few hours (DC 
Urea was precipitated out), followed by the addition of 
7-amino-3-methoxy-4-chloroisocoumarin (0.5 g, 2.2 
mmole). The reaction mixture was stirred at r.t. over-
night, and DC Urea was then filtered. The reaction 
mixture was evaporated to dryness, redissolved in 
CH2Ch and washed with 4% NaHC03. After evaporat-
ing the sovent, the residue was crystallized in THF-Pet 
Ether to give 0.2 g of Boc-alanylisocoumarin com-
pound, which was identified by NMR spectrum and 
was shown one spot on TLC. Boc-alanylisocoumarin 
EXAMPLES 
Preparation of 
3-(3-Aminopropoxy)-4-Chloroisocoumarin 
Hydrochloride 
60 (0.2 g) was stirred with 25 eq ofTFA (1.4 g) in CH2Ch 
at r.t. for half hour and 1 eq of 3.8N HCl/dioxane was 
then added. The product was precipitated out when 
anhydrous ether was added, and was purified by col-
0.13 g of 3-(3-aminopropoxy)isocoumarin hydrochlo- 65 
ride (0.5 mmole) was chlorinated with 0.007 g of N-
chlorosuccinimide (0.5 mmole) in 5 ml of DMF at r.t. 
overnight. The reaction mixture was purified by silica 
umn chromatography (CH2Ch:Me0H=7:1), yield 0.1 
g, one spot on TLC (CH2Ch:Me0H=7:1), NMR (d6-
DMSO): 87.4-8.4 (m, 3H), 4.0 (s, 3H), 3.1-3.6 (m, lH), 
1.5 (d, 3H). 
13 
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allowed to breathe spontaneously. The infusions of the 
inhibitor were given over a period of 13 to 15 minutes at 
a rate of 1 ml/min after a control APTT was drawn. 2 In vivo Test of 
7-Amino-3-(3-Isothiureidopropoxy)-4-
Chloroisocoumarin 5 ml of blood was drawn at various time for the determi-
nation of APTT. The blood was placed in citrated tubes 
and centrifuged at 12,000 g for 4 minutes at room tem-
perature. The platelet poor plasma thus obtained was 
This compound was dissolved in dimethyl sulfoxide 
(MeiSO) and diluted to a final concentration of 2% 
MeiSO in normal saline. The inhibitor concentrations 
tested were from 0.4 mg/ml to 1.2 mg/ml. Fourteen 
New Zealand White rabbits weighing 2.5-3.5 kg were 10 
anesthetized with intramuscular injection of ketamine 
and xylazine. Via cutdown, the external jugular vein 
was cannulated for the infusions and the carotid artery 
was cannulated for blood draws. The animals were 
placed on ice and APTT was determined in standard 
fashion and the data was shown in Table X. In another 
rabbit, the inhibitor was given at a concentration of0.8 
mg/ml over a 17 minute continuous infusion, and 
APTT and ACT were determined simutaneously at 
15 various time (data in Table XI). 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
bovine 
Inhibitors thrombinb 
3-(3-aminopropoxy)- 3.0 
isocoumarin 
3-(3-aminopropoxy)- 350 
4-chloroisocoumarin 
3-(2-isothiureidoethoxy)- 4,700 
4-chloroisocoumarin 
3-(3-isothiureidopropoxy)- 1,430 
4-chloroisocoumarin 
7-amino-3-(3-iso- 630 
thiureidopropoxy)-4-
chloroisocoumarin 
7-guanidino-3-methoxy- 4,900 
isocoumarin 
7-guanidino-3-methoxy- 290,000" 
4-chloroisocoumarin 
7-guanidino-3-ethoxy- 3,700 
isocoumarin 
7-guanidino-3-ethoxy- >55,ooom 
4-chloroisocoumarin 
7-guanidino-3-(2-phenyl- 5,700 
ethoxy)isocoumarin 
7-guanidino-3-(2-phenyl- >30,ooom 
ethoxy)-4-chloro-
isocoumarin 
7-(glycylamino)-3-methoxy- 51.5 
4-chloroisocoumarin 
7-(alanylamino)-3-methoxy- NI 
4-chloroisocoumarin 
TABLE I 
Inactivation Rates for Inhibition of Trypsin-Like Serine Proteases by Substituted lsocoumarins• 
ka~i/[lj (M- Is- I) 
porcine human 
bovine human pancreatic plasma human human 
factor xac factor xad kallikrein• kallikreinf factor Xlag factor xnah 
Nik 5.0 30 30 3.0 
160 860 1,400 380 190 
5,600 12,000 280,0001 44,000 39,000 
220 19,000 > 110,0001 47,000 27,000 
1,640 60 >110,000'" 1,100 22,000 6,200 
460 1,900 13,000 1,400 520 
3,100 11,000 45,000" 240,ooon 36,200 20,000 
2,700 16,000 44,000 3,100 1,300 
26,700 11,000 >200,ooom >500,0001 60,000 22,000 
11,000 16,000 62,000 1,200 690 
96,000 11,000 200,ooom >270,0001 20,000 26,000 
NI 
NI 
bovine 
trypsin; 
1,200 
7,600 
32,000 
46,000 
410,ooon 
3,300 
310,000" 
20,000 
>110,ooom 
45,000 
110,ooom 
32,100 
470 
human 
factor vnai 
450 
430 
2,200 
°Conditions were as 0.1 M Hepes, 0.01 CaCl2, pH 7.5 and 8-12% Me2SO and 25° C. Rate constants were measured by incubation method unless otherwise noted. An aliquot of inhibitor was added to an enzyme solution and aliquots 
removed with time and assayed for remaining enzymatic activity. First-order rate constants, kobs were obtained from the plots of In (v/v0 ) versus time. 
blnhibitor concentrations were from 0.3 to 400 µM. 
clnhibitor concentrations were from 0.4 to 310 µM. 
dtnhibitor concenlrations were from S lo IOS µM 
'lnhibitor concentrations were from 0.4 to 300 fLM 
ltnhibitor concentrations were from 0.3 to 300 µM. 
Kinhibitor concentrations were from 3 to 330 µM. 
11Inhibifor concencrations were from 3 to 330 µM. 
ilnhibitor concentrations were from l to 12 fLM. 
iinhibitor concentrations were from 5 to 44 µM. 
"No inhibition. 
1Inactivation was extremely rapid, and the k0 fo/[l] values were based on the residual enzymatic activity at 0.2 min. 
'"Second-order rate constant was obtained from same concentration of enzyme and inhibitor. 
n1nactivation rate constants were obtained by progress curve method described by Tian and Tsou, Biochemistry 21, I028-1032 (1982). 
1-l 
UI 
1-l 
Q\ 
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TABLE II 
Inactivation Rates of Inhibition of 
Coml!lement Proteins b;)'. Substituted Isocoumarins and APMSP. 
k1211i[!] (M-ls-12 
Inhibitors ob c2c C2aC BC Bbd cis-• Cir-/ 
APMSF 110 NIK NI NI NI 
3,4-dichloroisocoumarin 192 NI NI NI NI 170 42 
3-ethoxy-4-chloro- 0.2S NI NI NI NI 
isocoumarin 
7-amino-3-methoxy- 1.3 NI NI NI NI 
4-chloroisocoumarin 
3-(2-isothiureidoethoxy )- 61 l.S 1.4 13 IS 
4-chloroisocoumarin 
3-(3-isothiureidopropoxy )- 14S o.s 0.8 0.4 0.8 130,000 6,610 
4-chloroisocoumarin 
7-amino-3-(3-isothiureido- SS NI NI 23,000 1,320 
propoxy)-4-chloro-
isocoumarin 
7-guanidino-3-methoxy- 252 NI 28S 74 660 1S 
4-chloroisocoumarin' 
7-guanidino-3-ethoxy- 193 NI 167 95 690 239 
4-chloroisocoumarin 
7-guanidino-3-(2-phenyl- 92 NI 58 90 342 
ethoxy)-4-chloro-
isocoumarin 
"Conditions were 0.1 M Hepes, O.S M NaCl, pH 7.S, 8-10% MezSO and is• C. Inactivation rates 
were measured by incubation method. Enzyme concentrations were as follows: protein D, 1-9 µ.M; 
Cl, 0.7-111M; B, 1,8 11M; Bb 0.3-0.8 11M; Cls-, 0.o7 11M; Cir-, O.SI µ.M. 
bt:nhibitor concentrations were from 0.05 mM to 1.29 mM. 
CJ:nhibitor concentrations were from 0.19 mM to 1.25 mM. 
dlnhibitor concentrations were from 0.05 mM to 1.25 mM. 
'Inhibitor concentrations were from 0.8 µ.M to 44 µ.M. 
!Inhibitor concentrations were from 4.6 µ.M to 470 µ.M. 
KNo inhibition. 
TABLE III 
The Inactivation Rates of Sheep Lun~ Lymph Tryptasea, 
Human Lung Tnytasea and Rat Skin Trwtase by Substituted Isocoumarins. 
kgruf[I] (M- ls-1) 
Inhibitors 
3,4-dichloroisocoumarin 
3-(3-aminopropoxy)isocoumarin 
3-(3-aminopropoxy)-4-chloroisocoumarin 
3-(2-isothiureidoethoxy)-4-chloro-
isocoumarin 
s. L. TryptaseC 
39 
8.1 
18 
290 
3-(3-isothiureidopropoxy)-4-chloro- 230 
· isocoumarin 
7-amino-3-(3-isothiureidopropoxy)- 710 
4-chloroisocoumarin 
7-guanidino-3-methmcyisocoumarin 53 
7-guanidino-3-methoxy-4-chloroisocoumarin 620 
7-guanidino-3-ethoxyisocoumarin lSO 
7-guanidino-3-ethoxy-4-chloroisocoumarin 2,200 
7-guanidino-3-(2-phenylethoxy)isocoumarin lSO 
7-guanidino-3-(2-phenylethoxy)-4-chloro- 3,900 
isocoumarin 
APMSF 230 
H. L. Tryptased R. S. Tryptase• 
185 610 
2,000 8,370 
64,000 53,000 
28,000 63,000 
20,000 S2,000 
61,000 82,000 
S6,000 86,000 
"Inactivation rates were measured at 0.1 M Hepcs, O.S M NaCl, pH 7.S buffer, 8% MczSO and is• C. 
"Inactivation rates were measured at 2S mM phosphate, 0.S M NaCl, I mM EDTA, pH 7.S buffer, 9% MczSO and 25' C. 
'"Inhibitor concentrations were from 10 µ.M to 460 µ.M. 
dlnhibitor concentrations were from 0.4 µM to 40 µ.M. 
l'J:nhibitor concentrations were from 0.4 µ.M to 50 µM. 
frhe inhibition rate was measured at 0.1 M Hepcs, 0.5 M NaCl, pH 7.0, 25' C. 
TABLE IV 
Inactivation Rates for Inhibition of Serine Proteases by Substituted lsocoumarinsa 
Inhibitors 
3-(3-aminopropoxy)isocoumarin 
3-(3-aminopropoxy)-4-chloro-
isocoumarin 
3-(2-isothiureidoethoxy)-4-chloro-
isocoumarin 
3-(3-isothiureidopropoxy)-4-chloro-
isocoumarin 
7-amino-3-(3-isothiureidopropoxy)-
4-chloroisocoumarin 
7-guanidino-3-methoxyisocoumarin 
PPEh HLEc Chymotrypsind Cathepsin G' 
2.3 
70 
270 
70 
1.0 
SS 
47 
860 
220 
38 
580 
1,300 
2,000 1,700 
630 4,400 
320 270 
2.8 
260 
llO 
83 
36 
_f 
18 
19 20 
TABLE IV-continued 
Inactivation Rates for Inhibition of Serine Proteases b:z: Substituted Isocoumarins• 
kob,/[I] (M- 1s- 1) 
Inhibitors PPEb HLEC Chymotrypsind Cathepsin Ge 
7-guanidino-3-methoxy-4-chloro- 860 6,400 7,200 11,00) 
isocoumarin 
7-guanidino-3-ethoxyisocoumarin 86 1,900 990 _g 
7-guanidino-3-ethoxy-4-chloro 2,300 81,00) 37,00) 84,00) 
isocoumarin 
7-guanidino-3-(2-phenylethoxy)- Nih 0.89 2,600 _i 
isocoumarin 
7-guanidino-3-(2-phenylethoxy)- 5.7 73 38,00) 66,00) 
4-chlorioscoumarin 
7-(glycylamino)-3-methoxy- 1,960 7,710 4.9 
4-chloroisocoumarin 
7-(alanylamino)-3-methoxy- 1,610 13,500 20 
4-chloroisocoumarin 
alnactivation rates were measured at 0.1MHepes,0.5 NaCl, pH 7.5, 8-12% Me2SO and 25° C. by incubation 
method. 
An aliquot of inhibitor was added to a solution of enzyme and aliquots removed with time and assayed for 
remaining activity. 
hJ:nhibitor concentrations were from 0.01 to 0.51 mM. 
'"Inhibitor concentrations were from 0.001 to 0.18 mM. 
dlnhibitor concentrations were from O.CXJ4 to 0.33 mM. 
l'Jnhibitor concentrations were from 0.002 to 0.35 mM. 
linhibition was not time dependent, 81% inhibition was obtained at 0.49 mM. 
g'Jnhibition was not time dependent, 87% inhibition was obtained at 47 /J.M. 
hNo inhibition. 
;Inhibition was not time dependent, 87% inhibition was obtained at 0.53 mM. 
TABLE V 
Inactivation Rates for Inhibition of Chymases by Substituted 
Isocoumarinsa. 
Inhibitors 
7-guanidino-3-ethoxy-
4-chloroisocoumarin 
7-guanidino-3-(2-phenyl-
ethoxy )-4-chloro-
isocoumarin 
Rat Mast 
Cell 
Protease nb 
1100 
4100 
Human 
Skin 
Chymasec 
33 
22 
Human 
Lung 
Chymased 
540 
0 Inactivation rates were measured at 0.1 M Hepes, 0.5 M NaCl, pH 7.5, 8-12% 
Me2SO and 25" C. by incubation method. An aliquot of inhibitor was added to a 
solution of enzyme and aliquots were removed with time and assayed for the 
reinaining activity. 
frinhibitor concentration were from 0.007 mM to 0.013 mM. 
C'Jnhibitor concentration were from 0.41 mM to 0.53 mM. 
dlnhibitor concentration was 0.38 mM. 
TABLE VI 
Inactivation of Human Plasmin and Recombinant Human Tissue 
Plasmino1:1en Activator b:z: Substituted Isocoumarinsa. 
ka11,/[!] {M-ls-1} 
Plasminogen 
Plasminb Inhibitor Activatorc 
3,4-dichloroisocoumarin 73 
3-(3-aminopropoxy)isocoumarin 36 
3-(3-aminopropoxy )-4-chloroisocou- 770 10 94 
marin 
3-(3-isothiureidopropoxy)-4-chloro- 4,690 
isocoumarin 
7-amino-3-(3-isothiureido- 4,340 5,690 
propoxy)-4-chloroisocoumarin 
7-guanidino-3-methoxyisocoumarin 320 
7-guanidino-3-methoxy-4-chloro- 3,500 4,420 
isocoumarin 
7-guanidino-3-ethoxy-4-chloro- 12,320 7,720 
isocoumarin 
7-guanidino-3-(2-phenylethoxy)-4- 4,140 6,780 
chloro-isocoumarin 
7-(glycylamino )-3-methoxy-4-chloro- 1,470 
isocoumarin 
7-(alanylamino )-3-methoxy-4-chloro- 31 
35 
40 
45 
50 
55 
60 
65 
TABLE VI-continued 
Inactivation of Human Plasmin and Recombinant Human Tissue 
Plasminogen Activator by Substituted Isocoumarinsa. 
Inhibitor 
isocoumarin 
Plasminb 
Plasminogen 
Activatorc 
0 Inactivation constants were measured at 0.1 M Hepes, 0.5 M NaCl (or 0.01 M 
CaCli), pH 7.5, 8-12% Me2SO and 25" C. 
bynhibitor concentrations were from 4 µM to 330 µM. 
C'Jnhibitor concentrations were from 7 µM to 44 µM. 
TABLE VII 
Inactviation Rates of Mouse Granzyme A, Human Granzyme A 
and Q-13 Tryptase b:z: Substituted Isocoumarinsa. 
Mouse Human Human 
Inhibitors Granzyme Ab Granzyme Ab Q-31 Tryptasec 
3,4-dichloroiso- 50 50 29/ 
coumarin, 
3-(3-aminopro- 770 2,010 
poxy )-4-chloro-
isocoumarin 
3-(3-isothiureido- 17,500 18,420 12,830 
propoxy)-
4-chloro-
isocoumarin 
7-amino-3-(3- 3,00) 6,750 l,960 
isothiureido-
propoxy)-4-
chloro-
isocoumarin 
7-guanidino-3- 15,00) 6,620 
methoxy-
4-chloro-
isocoumarin 
7-guanidino-3- 26,200 6,850 6,180 
ethoxy-
4-chloro-
isocoumarin 
7-guanidino-3-(2· 6,400 l,880 
phenylethoxy)-
4-chloro-
21 
4,954,519 
TABLE VII-continued 
Inactviation Rates of Mouse Granzymc A, Human Granzymc A 
and Q-13 Tryptasc by Substituted Isocoumarins0 . 
Mouse Human Human 
Inhibitors Granzyme Ab Granzymc Ab Q-31 Tryptase< 
5 
22 
TABLE IX-continued 
Effect of Substituted Isocoumarins 
on PT and APTT of Human and Rabbit Plasma. 
Human 
Plasma Rabbit Plasma 
[I] PT APTT PT APTT 
isocoumarin 
Compounds (µM) (sec) (sec) (sec) (sec) 
62.00 
"Inactivation rates were measured at 0.1 M Hepes, O.oI M CaCl2. pH 7.5, 8% 
MeiSO and 2S" C. by incubation method. Z-Arg-SBzl (74-85 µM) was used as the 10 
substrate to monitor the residual enzymatic activity. 
131 
ap1asma and inhibitor were incubated at 37• C. for 1 min., Dade thromboplastin 
reagent was then added. 
6Ptasma and inhibitor were incubated at 37• C. for 3 min .• Orthobrain thromboplas· 
tin reagent was then added. 
binhibitor concentrations were from 0.4 µM to 45 µM. 
"Inhibitor concentrations were from 3 µM to 500 µM. 
TABLE VIII 
Half-Lives for Spontaneous Hydrolysis of lsocoumarin Derivatives 
in Hcpes BufferO, Human Plasma and Rabbit Plasma. 
t1 (min) 
Hepes Human Rabbit 
Compounds Buffer Plasma Plasma 
3-(3-aminopropoxy)isocoumarin 606 
3-(3-aminoprpoxy)-4-chlorosiso- 123 
coumarin 
3-(2-isothiureidoethoxy)-4-chloro 83 
isocoumarin 
3-(3-isothiureidopropoxy)-4-chloro-
isocoumarin 
7-amino-3-(3-isothiureidopropoxy)-
4-chloroisocoumarin 
7-guanidino-3-methoxyisocoumarin 
7-guanidino-3-mcthoxy-4-chloroiso-
coumarin 
7-guanidino-3-cthoxyisocoumarin 
7-guanidino-3-cthoxy-4-chloroiso-
coumarin 
7-guanidino-3-(2-phenylethoxy) 
isocoumarin 
7-guanidino-3-(2-phcnylethoxy)-4-
chloro-
isocoumarin 
99 
90 
252 
44 
136 
39 
140 
36 
0.5 
165 140 
6.7 
8.2 4.2 
4.5 
•conditions were 0.1 Hepes, 0.S M NaCl, pH 7.5 and 9% Me2SO at 25" C. Spontane-
ous hydrolysis rates were measured spectrophotometrically by monitoring the 
decrease in absorbance due to the isocoumarin ring system (wavelength 335-380 
nm) using the fint--0rdcr rate law. 
TABLE IX 
Effect of Substituted Isocoumarins 
on PT and APTT of Human and Rabbit Plasma. 
Compounds 
Control 
3,4-dichloroisocoumarin 
7-guanidino-3-mcthoxy-
4-chloro-isocoumarin 
7-guanidino-3-cthoxy-
4-chloro-isocoumarin 
7-guanidino-3-(2-phcnyl-
ethoxy)-4-
chloroisocoumarin 
3-(3-isothiureidopro-
poxy)-4-chloro-
isocoumarin 
7-amino-3-(3-isothiure-
idopropoxy )-4-chloro-
isocoumarin 
Human 
Plasma Rabbit Plasma 
[I] PT APTT PT APTT 
(µM) (sec) (sec) (sec) (sec) 
0 12.6 26.7 12.3° 19.0 
14.3b 
33 12.4 26.6 
45 26.0 
21 16.5 83.8 
4.3 74.8 
15 14.2° 
21 22.4 > 120 
31 27.4° 60.5 
11.2b 
53 31.4 > 120 
75 44.2 
107 80 > 120 
124 >12ob 
27 13.0 57.3 
31 12.3 25.8 
2.9 100.8 
29 19.4 > 120 
33 13.7° 68.6 
15 
TABLEX 
The in viro effect of 7-amino-4-chloro-3-(3-
isothiureidopropoxy)isocoumarin on APTT with continuous infusion 
to rabbits. 
APTT (sec) 
Dose at 0 min at 10 min at 25 min 
20 _,;(_m.;;;gl_ml_;.)_~(p:..r_e-_inf_us_io_n..;.) __ (~d-u_ri..;ng=-in_fu_s_io_n~)--(p"-o-s_t-_in_f_us_io_n..;.)_ 
25 
30 
35 
40 
0.4 19.0 35.5 
0.6 21.1 44.5 
0.8 19.4 49.9 
1.0 21.0 58.5 
1.2 21.0 72.1 
TABLE XI 
19.8 
22.6 
18.6 
17.6 
25.5 
The in viro effect of 7-amino-4-chloro-3-(3-
isothiureidopropoxy)isocoumarin on APTT and ACT with a 
uz,2/31 continuous infusion of 0.8 mg/ml to rabbits for 17 min. 
Time APTT ACT 
(min) (sec) (sec) 
0 19.2 175 
5 29.9 197 
10 43.4 265 
16 44.4 247 
22 IS.I 175 
29 18.1 165 
32 16.8 168 
37 17.4 180 
What is claimed is: 
1. A method of inhibiting blood clotting of mamma-
lian blood comprising contacting said blood with a 
therapeutically amount of a compound having the fol-
45 lowing structure: 
50 
55 or a pharmaceutically acceptable salt thereof, wherein 
R is selected from the group consisting of -N-
H-C( NH)NH2, -C( NH)NH2, amino-C1-6 
alkyl, and isothiureido-C1-6 alkyl, 
Z is selected from the group consisting of H, halogen, 
60 C1-6 alkyl, C1-6 alkyl with a phenyl group attached 
to the alkyl group, C1-6 fluorinated alkyl, C1-6 alkyl 
with a hydroxyl group attached to the alkyl group, 
C1-6 alkyl with a C1-6 alkoxy group attached to the 
alkyl group, C1-6 alkoxy, C1-6 fluorinated alkoxy, 
65 C1-6 alkoxy with a phenyl group attached to the 
alkoxy group, benzyloxy group wherein the phenyl 
group is unsubstituted or substituted by one or two 
substituents selected from halogen, trifluoro-
4,954,519 
24 23 
methyl, N02, cyano, methyl, methoxy, acetyl, car-
boxyl, OH, and amino, and 
Y is selected from the group consisting of H, halogen, 
trifluoromethyl, methyl, OH and methoxy. 
Y is selected from the group consisting ofH, halogen, 
trifluoromethyl, methyl, OH, and methoxy. 
2. A method of inhibiting clotting of mammalian 
blood comprising contacting said blood with a thera-
peutically effective amount of a compound having the 
following structure: 
3. A method of inhibiting clotting of mammalian 
blood comprising contacting said blood with a thera-
5 peutically effective amount of a compound having the 
following structure: 
0 
R~~ 
~z 
y 
or a pharmaceutically acceptable salt thereof, wherein 
10 
15 
Z is selected from the group consisting of C1-6 alkoxy 
with an amino group attached to the alkoxy group, 20 
C1-6 alkoxy with an isothiureido group attached to 
the alkoxy group, C1-6 alkoxy with a guanidino 
group attached to the alkoxy group, C1-6 alkoxy 
with an amidino group attached to the alkoxy 
group, C1-6 alkyl with an amino group attached to 25 
the alkyl group, C1-6 alkyl with an isothiureido 
group attached to the alkyl group, C1-6 alkyl with a 
guanidino group attached to the alkyl group, C1-6 
alkyl with an amidino group attached to the alkyl 
group, 30 
R is selected from the group consisting of H, OH, 
NH2, N02 halogen, C1-6 alkoxy, C1-6 fluorinated 
alkoxy, C1-6 alkyl, amino-C1-6 alkyl, 
M-AA-NH-, M-AA-0-, 
wherein AA represents alanine, valine, leucine, 35 
isoleucin, proline, methionine, phenylalanine, tryp-
tophan, glycine, serine, threonine, cysteine, tyro-
sine, asparagine, glutamine, aspartic acid, glutamic 
acid, lysine, arginine, histidine, beta-alanine, beta-
alanine, norleucine, norvaline, alpha-aminobutyric 40 
and epsilon-aminocaproic acid, citrulline, hydroxy-
proline, ornithine and sarcosine, 
wherein M represents H, lower alkanoyl having 1 to 
6 carbons, carboxyalkanoyl, hydroxyalkanoyl, 
amino-alkanoyl, benzene sulfonyl, tosyl, benzoyl, 45 
and lower alkyl sulfonyl having 1 to 6 carbons, and 
50 
55 
60 
65 
0 Rwll I a 
# # z 
y 
or a pharmaceutically acceptable salt thereof, wherein 
R is selected from the group consisting of -N-
H-C( NH)NH2, -C( NH)NH2, amino-Ct-6 
alkyl, isothiureido-C1-6 alkyl, 
Z is selected from the group consisting of C1-6 alkoxy 
with an amino group attached to the alkoxy group, 
C1-6 alkoxy with an isothiureido group attached to 
the alkoxy group, C1-6 alkoxy with a guanidino 
group attached to the alkoxy group, C1-6 alkoxy 
with an amidino group attached to the alkoxy 
group, C1-6 alkyl with an amino group attached to 
the alkyl group, C1-6 alkyl with an isothiureido 
group attached to the alkyl group, C1-6alkyl with a 
guanidino group attached to the alkyl group, Ct-6 
alkyl with an amidino group attached to the alkyl 
group, and 
Y is selected from the group consisting of H, halogen, 
trifluoromethyl, methyl, OH and methoxy. 
4. The method of claim 1 wherein said blood is circu-
lating within the body of the subject. 
5. The method of claim 2 wherein said blood is circu-
lating within the body of the subject. 
6. The method of claim 3 wherein said blood is circu-
lating within the body of the subject. 
7. The method of claim 1 wherein said blood is circu-
lating outside the body of the subject. 
8. The method of claim 2 wherein said blood is circu-
lating outside the body of the subject. 
9. The method of claim 3 wherein said blood is circu-
lating outside the body of the subject. 
* * * * * 
